GlassScriptPhysician profile
Mohammed I Hamdi
NPI 1982130035
$6,120.28
in general payments reported to CMS, 2019-2025
45 companies · $1,629 in 2025
The $1,629 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $126 · 2022: $1,275 · 2023: $1,550 · 2024: $1,540 · 2025: $1,629.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,719.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,719.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $882.36 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $458.34 | 2022-2025 | Jardiance, Zepbound, Mounjaro |
| Corcept Therapeutics | $414.52 | 2021-2025 | Korlym |
| Inspire Medical Systems, INC. | $395.75 | 2023-2025 | Inspire |
| Amgen INC. | $373.54 | 2022-2025 | Tepezza, Evenity, Repatha |
| Radius Health, INC. | $326.72 | 2024-2025 | Tymlos |
| Cequr Corporation | $307.62 | 2022-2025 | Cequr Simplicity |
| Alexion Pharmaceuticals, INC. | $255.18 | 2022-2024 | Ultomiris, Strensiq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $195.14 | 2022-2025 | Jardiance, Cyltezo |
| Bayer Healthcare Pharmaceuticals INC. | $184.40 | 2022-2025 | |
| Abbott Laboratories | $169.30 | 2024 | Freestyle Libre 3 |
| Tandem Diabetes Care, INC. | $166.45 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Beta Bionics, INC. | $164.86 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Recordati_rare_diseases_inc. | $162.84 | 2024-2025 | Isturisa, Signifor Lar |
| Abbvie INC. | $126.96 | 2024-2025 |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $120.79 | 2022-2025 | Gvoke Hypopen |
| Insulet Corporation | $112.72 | 2022-2025 | Omnipod |
| Sanofi-Aventis U.S. LLC | $107.16 | 2023-2025 | |
| Amneal Pharmaceuticals LLC | $105.75 | 2022-2025 | Unithroid |
| Novartis Pharmaceuticals Corporation | $88.09 | 2022-2025 | |
| Intuity Medical INC | $80.87 | 2022-2023 | Pogo Automatic Blood Glucose Monitoring System |
| Ibsa Pharma INC. | $74.77 | 2022-2023 | Tirosint, Licart |
| Astrazeneca Pharmaceuticals LP | $68.59 | 2022 | |
| Ascendis Pharma Endocrinology INC | $58.87 | 2025 | Yorvipath |
| Dexcom, INC. | $58.22 | 2022-2025 | Dexcom G6 Transmitter |
| Medtronic, INC. | $57.26 | 2023-2025 | Minimed 780g |
| Echosens North America, INC. | $50.34 | 2025 | Fibroscan |
| Sequel Med Tech, LLC | $48.58 | 2025 | Twiist |
| Sandoz INC. | $47.93 | 2023 | Hyrimoz |
| Avvisto Therapeutics, LLC | $44.04 | 2025 | Cycloset |
| Amryt Pharma Holdings LTD | $41.41 | 2022 | |
| Antares Pharma, INC. | $40.35 | 2024-2025 | Xyosted |
| Averitas Pharma INC. | $39.72 | 2024-2025 | Qutenza |
| Nevro Corp. | $36.68 | 2022 | |
| Neurocrine Biosciences, INC. | $36.36 | 2025 | |
| Pacira Pharmaceuticals Incorporated | $33.43 | 2023 | Exparel |
| Mallinckrodt Hospital Products INC. | $25.79 | 2023 | Acthar |
| Grt US Holding, INC. | $23.45 | 2022 | |
| Tersera Therapeutics LLC | $23.35 | 2023 | Quzyttir |
| Madrigal Pharmaceuticals | $22.54 | 2025 | Rezdiffra |
| Ultragenyx Pharmaceutical INC. | $21.27 | 2024 | Crysvita |
| Mannkind Corporation | $19.46 | 2023 | Afrezza |
| Esperion Therapeutics, INC. | $18.52 | 2022 | |
| Currax Pharmaceuticals LLC | $17.03 | 2023 | Contrave |
| Halozyme INC | $12.96 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammed Hamdi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.